What is the purpose of this trial?
The purpose of this study is to assess the safety, tolerability and biomarker efficacy of Gantenerumab and Solanezumab in individuals who have an autosomal dominant Alzheimer's disease (ADAD) mutation.
Ages: 18 - 80 years
Washington University School of Medicine
Start Date: 03/11/2014
End Date: 09/30/2023
Last Updated: 05/04/2018
Study HIC#: 1308012526